

# AP20187

## Catalog No: tcsc1953



### Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg



### Specifications

**CAS No:**

195514-80-8

**Formula:**

$C_{82}H_{107}N_5O_{20}$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 57$  mg/mL (38.44 mM)

**Alternative Names:**


B/B Homodimerizer

1482.75

AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize **FK506-binding protein (FKBP)** fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

**In Vitro:** When LNCaP cells are treated with AP20187 (B/B Homodimerizer) (100 nM), ro-iCaspase-9 levels are significantly reduced, and the smaller processed active caspase-9 becomes apparent<sup>[2]</sup>.

**In Vivo:** Real-time PCR analysis shows that AP20187 (B/B Homodimerizer) (0.5 mg/kg, 2 mg/kg, or 5 mg/kg) treatment significantly increases the levels of CHOP mRNA in the CNS of *PLP/Fv2E-PERK* mice at PID12. AP20187 treatment significantly alleviates EAE-induced myelin damage in these mice. AP20187 (B/B Homodimerizer) treatment significantly reduces the number of degenerating axons and increases the density of axons in the demyelinating lesions in the lumbar spinal cord of *PLP/Fv2E-PERK* mice<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!